Search tips
Search criteria 


Logo of neuroscibullNeuroscience Bulletin
Neurosci Bull. 2009 June; 25(3): 139–152.
Published online 2009 July 7. doi:  10.1007/s12264-009-0104-3
PMCID: PMC5552559

Language: English | Chinese

The mechanisms of brain ischemic insult and potential protective interventions



The mechanisms of brain ischemic insult include glutamate excitoxicity, calcium toxicity, free radicals, nitric oxide, inflammatory reactions, as well as dysfunctions of endoplasmic reticulum and mitochondrion. These injury cascades are interconnected in complex ways, thus it is hard to compare their pathogenic importances in ischemia models. And the research in cellular and molecular pathways has spurred the studies in potential neuroprotections mainly in pharmacological fields, such as anti-excitotoxic treatment, calcium-channel antagonism, approaches for inhibition of oxidation, inflammation and apoptosis, etc. Besides, other protective interventions including thrombolysis, arteriogenesis, regeneration therapy, and ischemia preconditioning or postconditioning, are also under investigations. Despite the present difficulties, we are quite optimistic towards future clinical applications of neuroprotective agents, by optimizing experimental approaches and clinical trials.

Key words: brain ischemia, glutamate receptors, calcium toxicity, endoplasmic reticulum stress, neuroprotection


脑缺血的损伤机制包括谷氨酸兴奋毒性、 钙毒性、 自由基、 一氧化氮、 炎性反应以及内质网和线粒体功能障碍等。 这些损伤性级联反应相互联系, 错综复杂, 很难比较它们在不同模型中的主次作用。 越来越多的对细胞及分子损伤途径的基础研究, 推动了对脑保护治疗的研究。 迄今为止, 脑保护治疗仍以药物治疗为主, 例如, 抗兴奋毒性治疗、 钙通道阻滞、 抗氧化、 抗炎、 抗凋亡治疗等。 此外一些研究还包括溶栓、 动脉生成和神经元再生, 以及缺血前适应和缺血后适应等。 虽然将这些研究成果应用于临床还存在许多困难, 但是通过改进动物实验和临床实验方法, 我们有理由对脑保护治疗持乐观的态度。

关键词: 脑缺血, 谷氨酸受体, 钙毒性, 内质网应激, 脑保护


[1] Ginsberg M.D. Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection: the 2002 Thomas Willis Lecture. Stroke. 2003;34(1):214–223. doi: 10.1161/01.STR.0000048846.09677.62. [PubMed] [Cross Ref]
[2] Heiss W.D., Kracht L.W., Thiel A., Grond M., Pawlik G. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. Brain. 2001;124(Pt1):20–29. doi: 10.1093/brain/124.1.20. [PubMed] [Cross Ref]
[3] Hossmann K.A. Pathophysiology and therapy of experimental stroke. Cell Mol Neurobiol. 2006;26(7–8):1057–1083. [PubMed]
[4] Ginsberg M.D. The New Language of Cerebral Ischemia. Am J Neuroradiol. 1997;18(8):1435–1445. [PubMed]
[5] Mehta S.L., Manhas N., Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev. 2007;54(1):34–66. doi: 10.1016/j.brainresrev.2006.11.003. [PubMed] [Cross Ref]
[6] Kristián T., Siesjö B.K. Calcium in ischemic cell death. Stroke. 1998;29(3):705–718. [PubMed]
[7] Chen M., Lu T.J., Chen X.J., Zhou Y., Chen Q., Feng X.Y., et al. Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke. 2008;39(11):3042–3048. doi: 10.1161/STROKEAHA.108.521898. [PubMed] [Cross Ref]
[8] Berridge M.J. Cell signalling. A tale of two messengers. Nature. 1993;365(6445):388–389. doi: 10.1038/365388a0. [PubMed] [Cross Ref]
[9] Paschen W. Disturbances of calcium homeostasis within the endoplasmic reticulum may contribute to the development of ischemic-cell damage. Med Hypotheses. 1996;47(4):283–288. doi: 10.1016/S0306-9877(96)90068-7. [PubMed] [Cross Ref]
[10] Sugimoto K., Iadecola C. Delayed effect of administration of COX-2 inhibitor in mice with acute cerebral ischemia. Brain Res. 2003;960(1–2):273–276. doi: 10.1016/S0006-8993(02)03805-2. [PubMed] [Cross Ref]
[11] Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., et al. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA. 2001;98(3):1294–1299. doi: 10.1073/pnas.98.3.1294. [PubMed] [Cross Ref]
[12] Xu X., Kim J.A., Zuo Z. Isoflurane preconditioning reduces mouse microglial activation and injury induced by lipopolysaccharide and interferon-gamma. Neuroscience. 2008;154(3):1002–1008. doi: 10.1016/j.neuroscience.2008.04.013. [PMC free article] [PubMed] [Cross Ref]
[13] Tikka T.M., Koistinaho J.E. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001;166(12):7527–7533. [PubMed]
[14] Swanson R.A., Ying W., Kauppinen T.M. Astrocyte influences on ischemic neuronal death. Curr Mol Med. 2004;4(2):193–205. doi: 10.2174/1566524043479185. [PubMed] [Cross Ref]
[15] Paschen W., Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration. Cell Calcium. 2005;38(3–4):409–415. doi: 10.1016/j.ceca.2005.06.019. [PubMed] [Cross Ref]
[16] Garaschuk O., Yaari Y., Konnerth A. Release and sequestration of calcium by ryanodine-sensitive stores in rat hippocampal neurones. J Physiol. 1997;502(Pt1):13–30. doi: 10.1111/j.1469-7793.1997.013bl.x. [PubMed] [Cross Ref]
[17] Verkhratsky A. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev. 2005;85(1):201–279. doi: 10.1152/physrev.00004.2004. [PubMed] [Cross Ref]
[18] Kaufman R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 1999;13(10):1211–1233. doi: 10.1101/gad.13.10.1211. [PubMed] [Cross Ref]
[19] Paschen W., Mengesdorf T. Cellular abnormalities linked to endoplasmic reticulum dysfunction in cerebrovascular disease—therapeutic potential. Pharmacol Ther. 2005;108(3):362–375. doi: 10.1016/j.pharmthera.2005.05.008. [PubMed] [Cross Ref]
[20] Harding H.P., Zhang Y., Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature. 1999;397(6716):271–274. doi: 10.1038/16729. [PubMed] [Cross Ref]
[21] Shen X., Ellis R.E., Lee K., Liu C.Y., Yang K., Solomon A., et al. Complementary signaling pathways regulate the unfolded protein response and are required for C. elegans development. Cell. 2001;107(7):893–903. doi: 10.1016/S0092-8674(01)00612-2. [PubMed] [Cross Ref]
[22] Yoshida H., Matsui T., Yamamoto A., Okada T., Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107(7):881–891. doi: 10.1016/S0092-8674(01)00611-0. [PubMed] [Cross Ref]
[23] Calfon M., Zeng H., Urano F., Till J.H., Hubbard S.R., Harding H.P., et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature. 2002;415(6867):92–96. doi: 10.1038/415092a. [PubMed] [Cross Ref]
[24] Harding H.P., Novoa I., Zhang Y., Zeng H., Wek R., Schapira M., et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000;6(5):1099–1108. doi: 10.1016/S1097-2765(00)00108-8. [PubMed] [Cross Ref]
[25] Harding H.P., Zhang Y., Zeng H., Novoa I., Lu P.D., Calfon M., et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003;11(3):619–633. doi: 10.1016/S1097-2765(03)00105-9. [PubMed] [Cross Ref]
[26] Novoa I., Zeng H., Harding H.P., Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001;153(5):1011–1022. doi: 10.1083/jcb.153.5.1011. [PMC free article] [PubMed] [Cross Ref]
[27] Luo S., Baumeister P., Yang S., Abcouwer S.F., Lee A.S. Induction of Grp78/BiP by translational block: activation of the Grp78 promoter by ATF4 through and upstream ATF/CRE site independent of the endoplasmic reticulum stress elements. J Biol Chem. 2003;278(39):37375–37385. doi: 10.1074/jbc.M303619200. [PubMed] [Cross Ref]
[28] Averous J., Bruhat A., Jousse C., Carraro V., Thiel G., Fafournoux P. Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation. J Biol Chem. 2004;279(7):5288–5297. doi: 10.1074/jbc.M311862200. [PubMed] [Cross Ref]
[29] Ma Y., Hendershot L.M. Herp is dually regulated by both the endoplasmic reticulum stress-specific branch of the unfolded protein response and a branch that is shared with other cellular stress pathways. J Biol Chem. 2004;279(14):13792–13799. doi: 10.1074/jbc.M313724200. [PubMed] [Cross Ref]
[30] Oyadomari S., Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 2004;11(4):381–389. doi: 10.1038/sj.cdd.4401373. [PubMed] [Cross Ref]
[31] Nakagawa T., Zhu H., Morishima N., Li E., Xu J., Yankner B.A., et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature. 2000;403(6765):98–103. doi: 10.1038/47513. [PubMed] [Cross Ref]
[32] Häcki J., Egger L., Monney L., Conus S., Rossé T., Fellay I., et al. Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene. 2000;19(19):2286–2295. doi: 10.1038/sj.onc.1203592. [PubMed] [Cross Ref]
[33] Boya P., Cohen I., Zamzami N., Vieira H.L., Kroemer G. Endoplasmic reticulum stress-induced cell death requires mitochondrial membrane permeabilization. Cell Death Differ. 2002;9(4):465–467. doi: 10.1038/sj.cdd.4401006. [PubMed] [Cross Ref]
[34] Germain M., Mathai J.P., Shore G.C. BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria. J Biol Chem. 2002;277(20):18053–18060. doi: 10.1074/jbc.M201235200. [PubMed] [Cross Ref]
[35] Hori O., Ichinoda F., Tamatani T., Yamaguchi A., Sato N., Ozawa K., et al. Transmission of cell stress from endoplasmic reticulum to mitochondria: enhanced expression of Lon protease. J Cell Biol. 2002;157(7):1151–1160. doi: 10.1083/jcb.200108103. [PMC free article] [PubMed] [Cross Ref]
[36] Lipton P. Ischemic cell death in brain neurons. Physiol Rev. 1999;79(4):1431–1568. [PubMed]
[37] Bursch W., Ellinger A., Kienzl H., Török L., Pandey S., Sikorska M., et al. Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis. 1996;17(8):1595–1607. doi: 10.1093/carcin/17.8.1595. [PubMed] [Cross Ref]
[38] Maiese K., Boniece I.R., Skurat K., Wagner J.A. Protein kinases modulate the sensitivity of hippocampal neurons to nitric oxide toxicity and anoxia. J Neurosci Res. 1993;36(1):77–87. doi: 10.1002/jnr.490360109. [PubMed] [Cross Ref]
[39] Bano D., Nicotera P. Ca2+ signals and neuronal death in brain ischemia. Stroke. 2007;38(2Suppl):674–676. doi: 10.1161/01.STR.0000256294.46009.29. [PubMed] [Cross Ref]
[40] Qin A.P., Zhang H.L., Qin Z.H. Mechanisms of lysosomal proteases participating in cerebral ischemia-induced neuronal death. Neurosci Bull. 2008;24(2):117–123. doi: 10.1007/s12264-008-0117-3. [PMC free article] [PubMed] [Cross Ref]
[41] Busch H.J., Buschmann I.R., Mies G., Bode C., Hossmann K.A. Arteriogenesis in hypoperfused rat brain. J Cereb Blood Flow Metab. 2003;23(5):621–628. doi: 10.1097/01.WCB.0000057741.00152.E4. [PubMed] [Cross Ref]
[42] Buschmann I.R., Busch H.J., Mies G., Hossmann K.A. Therapeutic induction of arteriogenesis in hypoperfused rat brain via granulocyte-macrophage colony-stimulating factor. Circulation. 2003;108(5):610–615. doi: 10.1161/01.CIR.0000074209.17561.99. [PubMed] [Cross Ref]
[43] Busch H.J., Buschmann I., Schneeloch E., Bode C., Mies G., Hossmann K.A. Therapeutically induced arteriogenesis in the brain. A new approach for the prevention of cerebral ischemia with vascular stenosis. Nervenarzt. 2006;77(2):215–220. doi: 10.1007/s00115-005-1988-4. [PubMed] [Cross Ref]
[44] Lees K.R. Cerestat and other NMDA antagonists in ischemic stroke. Neurology. 1997;49(5Suppl4):S66–69. [PubMed]
[45] Muir K.W., Lees K.R. Clinical experience with excitatory amino acid antagonist drugs. Stroke. 1995;26(3):503–513. [PubMed]
[46] Schachter S.C., Tarsy D. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000;9(4):871–883. doi: 10.1517/13543784.9.4.871. [PubMed] [Cross Ref]
[47] Kato T. Role of magnesium ions on the regulation of NMDA receptor—a pharmacopathology of memantine. Clin Calcium. 2004;14(8):76–80. [PubMed]
[48] Sun A., Cheng J. Novel targets for therapeutic intervention against ischemic brain injury. Clin Neuropharmacol. 1999;22(3):164–171. [PubMed]
[49] Gill R. The pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischaemia. Cerebrovasc Brain Metab Rev. 1994;6(3):225–256. [PubMed]
[50] Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (−)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA. 1998;95(14):8268–8273. doi: 10.1073/pnas.95.14.8268. [PubMed] [Cross Ref]
[51] Zhang Y., Deng P., Ruan Y., Xu Z.C. Dopamine D1-like receptors depress excitatory synaptic transmissions in striatal neurons after transient forebrain ischemia. Stroke. 2008;39(8):2370–2376. doi: 10.1161/STROKEAHA.107.506824. [PubMed] [Cross Ref]
[52] O’Neill M.J., Hicks C.A., Ward M.A., Cardwell G.P., Reymann J.M., Allain H., et al. Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. Eur J Pharmacol. 1998;352(1):37–46. doi: 10.1016/S0014-2999(98)00333-1. [PubMed] [Cross Ref]
[53] Kuhmonen J., Pokorný J., Miettinen R., Haapalinna A., Jolkkonen J., Riekkinen P., Sr, et al. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology. 1997;87(2):371–377. doi: 10.1097/00000542-199708000-00025. [PubMed] [Cross Ref]
[54] Marcoli M., Cervetto C., Castagnetta M., Sbaffi P., Maura G. 5-HT control of ischemia-evoked glutamate efflux from human cerebrocortical slices. Neurochem Int. 2004;45(5):687–691. doi: 10.1016/j.neuint.2004.03.004. [PubMed] [Cross Ref]
[55] Zhou C., Li C., Yu H.M., Zhang F., Han D., Zhang G.Y. Neuroprotection of gamma-aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric oxide synthase and PSD95 interaction and inhibited protein phosphatase activity in cerebral ischemia. J Neurosci Res. 2008;86(13):2973–2983. doi: 10.1002/jnr.21728. [PubMed] [Cross Ref]
[56] Zhang D.J., Xu G.R., Li Z.Y., Li Y.Z., Xu L.X., Lu F.Y., et al. The effects of Shuxuetong on the pathology of cerebral ischemia-reperfusion injury and GABA and TNF-alpha expression in gerbil models. Neurosci Bull. 2006;22(1):41–46. [PubMed]
[57] Stone T.W. Purines and neuroprotection. Adv Exp Med Biol. 2002;513:249–280. [PubMed]
[58] Schurr A. Neuroprotection against ischemic/hypoxic brain damage: blockers of ionotropic glutamate receptor and voltage sensitive calcium channels. Curr Drug Targets. 2004;5(7):603–618. doi: 10.2174/1389450043345209. [PubMed] [Cross Ref]
[59] Yenari M.A., Palmer J.T., Sun G.H., de Crespigny A., Mosely M.E., Steinberg G.K. Time-course and treatment response with SNX-111, an N-type calcium channel blocker, in a rodent model of focal cerebral ischemia using diffusion-weighted MRI. Brain Res. 1996;739(1–2):36–45. doi: 10.1016/S0006-8993(96)00808-6. [PubMed] [Cross Ref]
[60] Campbell C.A., Mackay K.B., Patel S., King P.D., Stretton J.L., Hadingham S.J., et al. Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats. Exp Neurol. 1997;148(1):45–50. doi: 10.1006/exnr.1997.6611. [PubMed] [Cross Ref]
[61] Xiong Z.G., Zhu X.M., Chu X.P., Minami M., Hey J., Wei W.L., et al. Neuroprotection in ischemia: blocking calcium-permeable acid-sensing ion channels. Cell. 2004;118(6):687–698. doi: 10.1016/j.cell.2004.08.026. [PubMed] [Cross Ref]
[62] Zhang H., Song L.C., Liu Y.Y., Ma Y., Lu Y.L. Pinacidil reduces neuronal apoptosis following cerebral ischemia-reperfusion in rats through both mitochondrial and death-receptor signal pathways. Neurosci Bull. 2007;23(3):145–150. doi: 10.1007/s12264-007-0021-2. [PMC free article] [PubMed] [Cross Ref]
[63] Sharma S.S., Gupta S. Neuroprotective effect of MnTMPyP, a superoxide dismutase/catalase mimetic in global cerebral ischemia is mediated through reduction of oxidative stress and DNA fragmentation. Eur J Pharmacol. 2007;561(1–3):72–79. doi: 10.1016/j.ejphar.2006.12.039. [PubMed] [Cross Ref]
[64] Park C.K., Hall E.D. Dose-response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia. Brain Res. 1994;645(1–2):157–163. [PubMed]
[65] Villa R.F., Gorini A. Pharmacology of lazaroids and brain energy metabolism: a review. Pharmacol Rev. 1997;49(1):99–136. [PubMed]
[66] Yoshida H., Yanai H., Namiki Y., Fukatsu-Sasaki K., Furutani N., Tada N. Neuroprotective effects of edaravone: a novel free radical scavenger in cerebrovascular injury. CNS Drug Rev. 2006;12(1):9–20. doi: 10.1111/j.1527-3458.2006.00009.x. [PubMed] [Cross Ref]
[67] MacGregor D.G., Avshalumov M.V., Rice M.E. Brain edema induced by in vitro ischemia: causal factors and neuroprotection. J Neurochem. 2003;85(6):1402–1411. doi: 10.1046/j.1471-4159.2003.01772.x. [PubMed] [Cross Ref]
[68] Lapchak P.A., Araujo D.M., Song D., Wei J., Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl] benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke. 2002;33(5):1411–1415. doi: 10.1161/01.STR.0000015346.00054.8B. [PubMed] [Cross Ref]
[69] Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999;30(9):1969–1973. [PubMed]
[70] Cai Z.Y., Yan Y., Sun S.Q., Zhang J., Huang L.G., Yan N., et al. Minocycline attenuates cognitive impairment and restrains oxidative stress in the hippocampus of rats with chronic cerebral hypoperfusion. Neurosci Bull. 2008;24(5):305–313. doi: 10.1007/s12264-008-0324-y. [PMC free article] [PubMed] [Cross Ref]
[71] Bartus R.T., Baker K.L., Heiser A.D., Sawyer S.D., Dean R.L., Elliott P.J., et al. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab. 1994;14(4):537–544. [PubMed]
[72] Liao S.L., Chen W.Y., Raung S.L., Chen C.J. Neuroprotection of naloxone against ischemic injury in rats: role of mu receptor antagonism. Neurosci Lett. 2003;345(3):169–172. doi: 10.1016/S0304-3940(03)00540-8. [PubMed] [Cross Ref]
[73] Yenari M.A., Kunis D., Sun G.H., Onley D., Watson L., Turner S., et al. Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin, reduces injury in a rabbit model of transient focal cerebral ischemia. Exp Neurol. 1998;153(2):223–233. doi: 10.1006/exnr.1998.6876. [PubMed] [Cross Ref]
[74] Morales J.R., Ballesteros I., Deniz J.M., Hurtado O., Vivancos J., Nombela F., et al. Activation of liver X receptors promotes neuroprotection and reduces brain inflammation in experimental stroke. Circulation. 2008;118(14):1450–1459. doi: 10.1161/CIRCULATIONAHA.108.782300. [PubMed] [Cross Ref]
[75] Szydlowska K., Zawadzka M., Kaminska B. Neuroprotectant FK506 inhibits glutamate-induced apoptosis of astrocytes in vitro and in vivo. J Neurochem. 2006;99(3):965–975. doi: 10.1111/j.1471-4159.2006.04136.x. [PubMed] [Cross Ref]
[76] Ebisu T., Mori Y., Katsuta K., Fujikawa A., Matsuoka N., Aoki I., et al. Neuroprotective effects of an immunosuppressant agent on diffusion/perfusion mismatch in transient focal ischemia. Magn Reson Med. 2004;51(6):1173–1180. doi: 10.1002/mrm.20087. [PubMed] [Cross Ref]
[77] Uchino H., Morota S., Takahashi T., Ikeda Y., Kudo Y., Ishii N., et al. A novel neuroprotective compound FR901459 with dual inhibition of calcineurin and cyclophilins. Acta Neurochir Suppl. 2006;96:157–162. doi: 10.1007/3-211-30714-1_35. [PubMed] [Cross Ref]
[78] Kaminska B., Gaweda-Walerych K., Zawadzka M. Molecular mechanisms of neuroprotective action of immunosuppressants—facts and hypotheses. J Cell Mol Med. 2004;8(1):45–58. doi: 10.1111/j.1582-4934.2004.tb00259.x. [PubMed] [Cross Ref]
[79] Pedata F., Gianfriddo M., Turchi D., Melani A. The protective effect of adenosine A2A receptor antagonism in cerebral ischemia. Neurol Res. 2005;27(2):169–174. doi: 10.1179/016164105X21913. [PubMed] [Cross Ref]
[80] Brambilla R., Cottini L., Fumagalli M., Ceruti S., Abbracchio M.P. Blockade of A2A adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. Glia. 2003;43(2):190–194. doi: 10.1002/glia.10243. [PubMed] [Cross Ref]
[81] Han B.H., Holtzman D.M. BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J Neurosci. 2000;20(15):5775–5781. [PubMed]
[82] Robertson G.S., Crocker S.J., Nicholson D.W., Schulz J.B. Neuroprotection by the inhibition of apoptosis. Brain Pathol. 2000;10(2):283–292. doi: 10.1111/j.1750-3639.2000.tb00262.x. [PubMed] [Cross Ref]
[83] Hoffman G.E., Merchenthaler I., Zup S.L. Neuroprotection by ovarian hormones in animal models of neurological disease. Endocrine. 2006;29(2):217–231. doi: 10.1385/ENDO:29:2:217. [PubMed] [Cross Ref]
[84] Kotani Y., Shimazawa M., Yoshimura S., Iwama T., Hara H. The experimental and clinical pharmacology of propofol, an anesthetic agent with neuroprotective properties. CNS Neurosci Ther. 2008;14(2):95–106. doi: 10.1111/j.1527-3458.2008.00043.x. [PubMed] [Cross Ref]
[85] Luo Y., Ma D., Ieong E., Sanders R.D., Yu B., Hossain M., et al. Xenon and sevoflurane protect against brain injury in a neonatal asphyxia model. Anesthesiology. 2008;109(5):782–789. doi: 10.1097/ALN.0b013e3181895f88. [PubMed] [Cross Ref]
[86] Schmid-Elsaesser R., Hungerhuber E., Zausinger S., Baethmann A., Reulen H.J. Combination drug therapy and mild hypothermia: a promising treatment strategy for reversible, focal cerebral ischemia. Stroke. 1999;30(9):1891–1899. [PubMed]
[87] Wang X.S., Ruan X.Z., Wang W. Protective Effect of Ginkgo Biloba Extract on Brain Injury Induced by Ischemia/Reperfusion in Rats. J Huazhong Univ Sci Tech[Health Sci] 2003;32(5):500–502.
[88] Hu X.S., Zhou D., Zhou D.M. Protective effects of PTS on cerebral ischemia—reperfusion injury in rat. J Apoplexy and Nervous Disease. 2004;21(4):354–356.
[89] Wu H.Q., Chang M.Z., Zhang G.L., Zhao Y.X. The mechanism of protective effects of puerarin on learning-memory disorder after global cerebral ischemic reperfusive injury in rats. J Apoplexy and Nervous Disease. 2004;21(4):350–353.
[90] Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab. 2002;22(11):1283–1296. doi: 10.1097/00004647-200211000-00001. [PubMed] [Cross Ref]
[91] Stagliano N.E., Pérez-Pinzón M.A., Moskowitz M.A., Huang P.L. Focal ischemic preconditioning induces rapid tolerance to middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab. 1999;19(7):757–761. doi: 10.1097/00004647-199907000-00005. [PubMed] [Cross Ref]
[92] Dirnagl U., Simon R.P., Hallenbeck J.M. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 2003;26(5):248–254. doi: 10.1016/S0166-2236(03)00071-7. [PubMed] [Cross Ref]
[93] Ge P.F., Luo T.F., Zhang J.Z., Chen D.W., Luan Y.X., Fu S.L. Ischemic preconditioning induces chaperone hsp70 expression and inhibits protein aggregation in the CA1 neurons of rats. Neurosci Bull. 2008;24(5):288–296. doi: 10.1007/s12264-008-0623-3. [PMC free article] [PubMed] [Cross Ref]
[94] Obrenovitch T.P. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol Rev. 2008;88(1):211–247. doi: 10.1152/physrev.00039.2006. [PubMed] [Cross Ref]
[95] Xing B., Chen H., Zhang M., Zhao D., Jiang R., Liu X., et al. Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat. Stroke. 2008;39(8):2362–2369. doi: 10.1161/STROKEAHA.107.507939. [PubMed] [Cross Ref]
[96] Wang J.Y., Shen J., Gao Q., Ye Z.G., Yang S.Y., Liang H.W., et al. Ischemic postconditioning protects against global cerebral ischemia/reperfusion-induced injury in rats. Stroke. 2008;39(3):983–990. doi: 10.1161/STROKEAHA.107.499079. [PubMed] [Cross Ref]
[97] Faden A.I., Stoica B. Neuroprotection: challenges and opportunities. Arch Neurol. 2007;64(6):794–800. doi: 10.1001/archneur.64.6.794. [PubMed] [Cross Ref]

Articles from Neuroscience Bulletin are provided here courtesy of Springer